NCT05354453View on ClinicalTrials.gov

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0001)

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

May 23, 2022

Primary Completion Date

June 14, 2023

Study Completion Date

June 14, 2023

Conditions
Healthy
Interventions
DRUG

BI 1839100

BI 1839100

DRUG

Placebo

Placebo

DRUG

allyl isothiocyanate (AITC)

allyl isothiocyanate (AITC)

Trial Locations (1)

2333 CL

Centre Human Drug Research, Leiden

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05354453 - A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0001) | Biotech Hunter | Biotech Hunter